Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Alexion Pharmaceuticals Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Alexion Pharmaceuticals Inc. market cap is $40.34B.
What is the 52-week high for Alexion Pharmaceuticals Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Alexion Pharmaceuticals Inc. 52 week high is $187.45 as of October 01, 2025.
What is the 52-week low for Alexion Pharmaceuticals Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Alexion Pharmaceuticals Inc. 52 week low is $99.91 as of October 01, 2025.
What is Alexion Pharmaceuticals Inc. stock price today?
Alexion Pharmaceuticals Inc. stock price today is $182.50.
What was Alexion Pharmaceuticals Inc. stock price yesterday?
Alexion Pharmaceuticals Inc. stock price yesterday was $179.45.
What is the PE ratio of Alexion Pharmaceuticals Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Alexion Pharmaceuticals Inc.’s P/E ratio is 59.70.
What is the Price-to-Book ratio of Alexion Pharmaceuticals Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Alexion Pharmaceuticals Inc. P/B ratio is 3.2468.
What is the 50-day moving average of Alexion Pharmaceuticals Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Alexion Pharmaceuticals Inc. 50-day moving average is $179.76.